公开(公告)号：US20140051657A1

公开(公告)日：2014-02-20

申请号：US13964684

申请日：2013-08-12

Applicant: Baxter Healthcare S.A. ,  Baxter International Inc.

Inventor： Michael Dockal ,  Friedrich Scheiflinger ,  Zhenqing Zhang ,  Susanne Till ,  Sabine Knappe ,  Christina Szabo

IPC: G01N33/86

CPC classification number: G01N33/86

Abstract: Aspects of the invention include methods for identifying one or more NASP (non-anticoagulant sulfated polysaccharide) compositions that are suitable for treating a subject having a blood coagulation disorder. In practicing methods according to certain embodiments, NASP compositions are evaluated by determining the coagulation activity and chemical makeup of the NASP composition and the molecular structure of the NASP. Systems for practicing methods of the invention as well as compositions suitable for treating a subject having a blood coagulation disorder are also described.

Abstract translation: 本发明的方面包括用于鉴定适合于治疗具有凝血障碍的受试者的一种或多种NASP（非抗凝血硫酸多糖）组合物的方法。 在根据某些实施方案的实践方法中，通过测定NASP组合物的凝血活性和化学组成以及NASP的分子结构来评估NASP组合物。 还描述了用于本发明的实践方法的系统以及适合于治疗具有凝血障碍的受试者的组合物。

公开(公告)号：US09417251B2

公开(公告)日：2016-08-16

申请号：US13964684

申请日：2013-08-12

Applicant: Baxter International Inc. ,  Baxter Healthcare S.A.

Inventor： Michael Dockal ,  Friedrich Scheiflinger ,  Zhenqing Zhang ,  Susanne Till ,  Sabine Knappe ,  Christina Szabo

IPC: G01N33/86

CPC classification number: G01N33/86

Abstract: Aspects of the invention include methods for identifying one or more NASP (non-anticoagulant sulfated polysaccharide) compositions that are suitable for treating a subject having a blood coagulation disorder. In practicing methods according to certain embodiments, NASP compositions are evaluated by determining the coagulation activity and chemical makeup of the NASP composition and the molecular structure of the NASP. Systems for practicing methods of the invention as well as compositions suitable for treating a subject having a blood coagulation disorder are also described.

Abstract translation: 本发明的方面包括用于鉴定适合于治疗具有凝血障碍的受试者的一种或多种NASP（非抗凝血硫酸多糖）组合物的方法。 在根据某些实施方案的实践方法中，通过测定NASP组合物的凝血活性和化学组成以及NASP的分子结构来评估NASP组合物。 还描述了用于本发明的实践方法的系统以及适合于治疗具有凝血障碍的受试者的组合物。

公开(公告)号：US20130209444A1

公开(公告)日：2013-08-15

申请号：US13754575

申请日：2013-01-30

Applicant: Baxter International Inc. ,  Baxter Healthcare S.A.

Inventor： Michael Dockal ,  Fritz Scheiflinger ,  Sabine Knappe ,  Susanne Till ,  Ton Hai ,  Paul Sanders ,  Prasad Dande ,  Cong Jiang

IPC: A61K31/737 ,  C08B37/16 ,  A61K45/06 ,  C07H5/10

CPC classification number: A61K31/737 ,  A61K31/715 ,  A61K45/06 ,  C07H5/10 ,  C08B37/0012 ,  A61K2300/00

Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

Abstract translation: 本发明提供非抗凝血剂硫酸化或磺化多糖（NASP），其加速凝血过程。 还提供了包含本发明的NASP与药学上可接受的赋形剂的药物制剂，并且在各种实施方案中，这些制剂是单位剂量制剂。 本发明提供了口服生物可利用的NASP制剂。 还提供了利用本发明的化合物和制剂在体内促进凝血作为治疗和预防剂的方法，并且在体外作为血液凝固过程的研究的辅助。

公开(公告)号：US20130202550A1

公开(公告)日：2013-08-08

申请号：US13754727

申请日：2013-01-30

Applicant: Baxter International Inc. ,  Baxter Healthcare S.A.

Inventor： Michael Dockal ,  Fritz Scheiflinger ,  Sabine Knappe ,  Susanne Till ,  Ton Hai ,  Paul Sanders

IPC: A61K31/795

CPC classification number: A61K31/795 ,  A61K31/37 ,  A61K31/7024 ,  A61K31/727 ,  A61K38/37 ,  A61K38/4846 ,  A61K2300/00

Abstract: The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.

Abstract translation: 本发明提供药物制剂，其包含与至少一种硫酸盐或磺酸盐部分的非抗凝血剂，非糖类聚合物。 本发明的药物制剂可用于改善受试者的血液凝固。 还提供了使用这些聚合物来查询体外血液凝固动力学的有用的分析方法。

公开(公告)号：US20150258182A1

公开(公告)日：2015-09-17

申请号：US14658006

申请日：2015-03-13

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： Michael Dockal ,  Sabine Knappe ,  Susanne Till ,  Friedrich Scheiflinger ,  Peter Leopold Turecek

IPC: A61K38/48

CPC classification number: A61K38/4833 ,  A61K38/4846 ,  A61K38/54 ,  C12Y304/21005 ,  C12Y304/21006

Abstract: Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein.

Abstract translation: 本文公开了用于改善止血治疗出血性疾病和逆转抗凝活性的组合物和方法。 本文描述了治疗与FEIBA®有效但需要较低FII浓度的出血性疾病有关的凝血酶原（FII）和活化因子X（FXa）的有效比例。